Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

Publisher： Karger

E-ISSN： 1421-9662|118|1|7-9

ISSN： 0001-5792

Source： Acta Haematologica, Vol.118, Iss.1, 2007-03, pp. : 7-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : 483-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pilot Remission Induction Therapy with Idarubicin, plus an Intensified Dose of Ara-C and Priming with Granulocyte Colony-Stimulating Factor for Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 109-114

Karger

Access to resources Recommend Favorite

Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 15-16

Karger

Access to resources Recommend Favorite

Takotsubo Cardiomyopathy after Systemic Consolidation Therapy with High-Dose Intravenous Cytarabine in a Patient with Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 37, Iss. 9, 2014-07 ,pp. : 487-490

Karger

Access to resources Recommend Favorite

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 4036-4043

John Wiley & Sons Inc

Access to resources Recommend Favorite